Alkermes (ALKS) Non-Current Debt (2011 - 2026)
Alkermes' (ALKS) quarterly Non-Current Debt came in at $1.5 billion in Q1 2026, up 419.15% on a QoQ basis from $285.8 million in Q3 2024.
Alkermes (ALKS) Non-Current Debt (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 15 years of Non-Current Debt data on file, last reported at $1.5 billion in Q1 2026.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a N/A change from a year earlier, with the FY2023 full-year figure at $287.7 million, down 0.88% from the prior year.
- Non-Current Debt for Q1 2026 stood at $1.5 billion, up from $285.8 million in the prior quarter.
- Over the last five years, Non-Current Debt for ALKS reached as high as $1.5 billion in Q1 2026 and fell as low as $285.8 million in Q3 2024.
- Historically, Non-Current Debt has averaged $388.6 million across 4 years, with a median of $289.3 million in 2023.
- Across the five-year window, Non-Current Debt declined 0.86% in 2022 and declined 0.88% in 2024, its largest moves.
- Year by year, Non-Current Debt stood at $290.3 million in 2022, then declined by 0.88% to $287.7 million in 2023, then decreased by 0.66% to $285.8 million in 2024, then jumped by 419.15% to $1.5 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $1.5 billion in Q1 2026, $285.8 million in Q3 2024, and $286.5 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 1.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.48 Bn |
| Sep 30, 2024 | 285.82 Mn |
| Jun 30, 2024 | 286.46 Mn |
| Mar 31, 2024 | 287.10 Mn |
| Dec 31, 2023 | 287.73 Mn |
| Sep 30, 2023 | 288.37 Mn |
| Jun 30, 2023 | 289.00 Mn |
| Mar 31, 2023 | 289.64 Mn |
| Dec 31, 2022 | 290.27 Mn |
| Sep 30, 2022 | 290.90 Mn |
| Jun 30, 2022 | 291.54 Mn |
| Mar 31, 2022 | 292.17 Mn |
| Dec 31, 2021 | 292.80 Mn |
| Sep 30, 2021 | 293.44 Mn |
| Jun 30, 2021 | 294.07 Mn |
| Mar 31, 2021 | 294.70 Mn |
| Dec 31, 2020 | 272.12 Mn |
| Sep 30, 2020 | 272.66 Mn |
| Jun 30, 2020 | 273.21 Mn |
| Mar 31, 2020 | 273.75 Mn |